Ono sets up subsidiary in South Korea

14 October 2013

Japanese drugmaker Ono Pharmaceutical (TYO: 4528) has decided to establish a new fully owned subsidiary in South Korea. A name for the new affiliate has not yet been decided.

Ono established a Seoul branch in April 2001 in South Korea, and has been supporting local development and promotion activities of ONO Products by its licensees, Dong-A ST and Ilsung Pharmaceutical.

While Ono continues to support for promotion of licensees through the subsidiary in scientific aspect in South Korea, where the demand for pharmaceuticals will be increased, Ono plans to commercialize specialty products such as anti-cancer agents through the subsidiary in the future.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >